Zealand Pharma A/S (ZLDPF)
USD 62.5
(0.0%)
USD 62.5
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -703.73 Million DKK | 27.12% |
| 2022 | -965.61 Million DKK | 5.16% |
| 2021 | -1.01 Billion DKK | -20.24% |
| 2020 | -846.72 Million DKK | -48.15% |
| 2019 | -571.54 Million DKK | -198.32% |
| 2018 | 581.27 Million DKK | 313.49% |
| 2017 | -272.27 Million DKK | -76.9% |
| 2016 | -153.91 Million DKK | -35.06% |
| 2015 | -113.95 Million DKK | -75.35% |
| 2014 | -64.99 Million DKK | 64.62% |
| 2013 | -183.67 Million DKK | -604.99% |
| 2012 | 36.37 Million DKK | 171.9% |
| 2011 | 13.37 Million DKK | 112.78% |
| 2010 | -104.63 Million DKK | -38.2% |
| 2009 | -75.71 Million DKK | -124.45% |
| 2008 | -33.73 Million DKK | 38.67% |
| 2007 | -55 Million DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -292.75 Million DKK | -28.04% |
| 2024 Q1 | -228.64 Million DKK | 13.64% |
| 2023 Q1 | -193.63 Million DKK | 39.69% |
| 2023 FY | -703.73 Million DKK | 27.12% |
| 2023 Q4 | -264.75 Million DKK | -457.07% |
| 2023 Q3 | 74.14 Million DKK | 123.21% |
| 2023 Q2 | -319.5 Million DKK | -65.0% |
| 2022 Q4 | -321.06 Million DKK | -111.39% |
| 2022 FY | -965.61 Million DKK | 5.16% |
| 2022 Q3 | -151.88 Million DKK | 64.88% |
| 2022 Q2 | -432.43 Million DKK | -138.86% |
| 2022 Q1 | -181.04 Million DKK | 35.4% |
| 2021 Q4 | -280.26 Million DKK | -40.92% |
| 2021 Q2 | -296.81 Million DKK | -22.56% |
| 2021 FY | -1.01 Billion DKK | -20.24% |
| 2021 Q1 | -242.18 Million DKK | 36.36% |
| 2021 Q3 | -198.88 Million DKK | 32.99% |
| 2020 Q3 | -228.57 Million DKK | -292.87% |
| 2020 Q2 | -58.18 Million DKK | 67.59% |
| 2020 FY | -846.72 Million DKK | -48.15% |
| 2020 Q1 | -179.51 Million DKK | 7.31% |
| 2020 Q4 | -380.54 Million DKK | -66.49% |
| 2019 FY | -571.54 Million DKK | -198.32% |
| 2019 Q1 | -127.51 Million DKK | -3.69% |
| 2019 Q2 | -137.12 Million DKK | -7.54% |
| 2019 Q3 | -113.22 Million DKK | 17.43% |
| 2019 Q4 | -193.67 Million DKK | -71.05% |
| 2018 Q4 | -122.97 Million DKK | -113.38% |
| 2018 Q2 | -127.16 Million DKK | -39.12% |
| 2018 Q1 | -91.4 Million DKK | 16.91% |
| 2018 FY | 581.27 Million DKK | 313.49% |
| 2018 Q3 | 919.31 Million DKK | 822.94% |
| 2017 Q2 | -93.67 Million DKK | -255.81% |
| 2017 FY | -272.27 Million DKK | -76.9% |
| 2017 Q4 | -110 Million DKK | -160.28% |
| 2017 Q3 | -42.26 Million DKK | 54.88% |
| 2017 Q1 | -26.32 Million DKK | -149.92% |
| 2016 Q1 | -72.79 Million DKK | -204.41% |
| 2016 Q4 | 52.74 Million DKK | 270.67% |
| 2016 Q3 | -30.9 Million DKK | 68.45% |
| 2016 Q2 | -97.93 Million DKK | -34.55% |
| 2016 FY | -153.91 Million DKK | -35.06% |
| 2015 Q2 | -76.8 Million DKK | -38.27% |
| 2015 Q4 | 69.72 Million DKK | 235.85% |
| 2015 FY | -113.95 Million DKK | -75.35% |
| 2015 Q1 | -55.54 Million DKK | 11.78% |
| 2015 Q3 | -51.32 Million DKK | 33.18% |
| 2014 Q3 | 16.86 Million DKK | 135.33% |
| 2014 Q4 | -62.96 Million DKK | -473.34% |
| 2014 FY | -64.99 Million DKK | 64.62% |
| 2014 Q1 | 28.85 Million DKK | 164.43% |
| 2014 Q2 | -47.74 Million DKK | -265.48% |
| 2013 FY | -183.67 Million DKK | -604.99% |
| 2013 Q4 | -44.77 Million DKK | -29.45% |
| 2013 Q3 | -34.58 Million DKK | 26.39% |
| 2013 Q2 | -46.98 Million DKK | 18.04% |
| 2013 Q1 | -57.32 Million DKK | -9.27% |
| 2012 Q2 | 23.73 Million DKK | -63.87% |
| 2012 Q1 | 65.68 Million DKK | 442.74% |
| 2012 FY | 36.37 Million DKK | 171.9% |
| 2012 Q4 | -52.46 Million DKK | -8898.97% |
| 2012 Q3 | -583 Thousand DKK | -102.46% |
| 2011 Q2 | 91.75 Million DKK | 304.34% |
| 2011 Q4 | -19.16 Million DKK | -33.93% |
| 2011 Q1 | -44.9 Million DKK | 28.36% |
| 2011 FY | 13.37 Million DKK | 112.78% |
| 2011 Q3 | -14.31 Million DKK | -115.6% |
| 2010 Q1 | -23.13 Million DKK | 0.0% |
| 2010 FY | -104.63 Million DKK | -38.2% |
| 2010 Q2 | 36.32 Million DKK | 257.01% |
| 2010 Q3 | -55.14 Million DKK | -251.83% |
| 2010 Q4 | -62.67 Million DKK | -13.66% |
| 2009 FY | -75.71 Million DKK | -124.45% |
| 2008 FY | -33.73 Million DKK | 38.67% |
| 2007 FY | -55 Million DKK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | -18327.311% |
| Skye Bioscience, Inc. | -37.64 Million USD | -1769.42% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 1180.466% |
| Nascent Biotech, Inc. | -2.08 Million USD | -33609.109% |
| Qrons Inc. | -789.34 Thousand USD | -89054.58% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -169280.161% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -9978.126% |
| BioStem Technologies, Inc. | -8.48 Million USD | -8195.89% |
| Regen BioPharma, Inc. | 1.02 Million USD | 68857.548% |
| CSL Limited | 2.64 Billion USD | 126.637% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -1024.202% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 1428.336% |
| Rebus Holdings, Inc. | -1.02 Million USD | -68894.02% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -52597.519% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -111179.445% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -4333.995% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -838.782% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -10601.446% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -257300.824% |
| SQZ Biotechnologies Company | -79.46 Million USD | -785.607% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -24230.676% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -38555.764% |
| Mesoblast Limited | -87.95 Million USD | -700.103% |
| Marizyme, Inc. | -65.34 Million USD | -976.928% |
| Genus plc | 7.9 Million USD | 9008.089% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -6361.217% |
| Pharming Group N.V. | -10.54 Million USD | -6571.777% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -32333.149% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -18867.51% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -7857.248% |
| ContraFect Corporation | -65.15 Million USD | -980.133% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -14302.987% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -40638.485% |
| IMV Inc. | -36.48 Million USD | -1828.808% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -8631.598% |
| MultiCell Technologies, Inc. | -380.07 USD | -185160265.196% |
| ONE Bio Corp. | 8.67 Million USD | 8210.758% |
| Accustem Sciences Inc. | -3.74 Million USD | -18684.311% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -1261.408% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -55437.852% |
| Q BioMed Inc. | -2.05 Million USD | -34193.719% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -18751.835% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -29458.061% |
| Biomind Labs Inc. | -1.21 Million USD | -57853.388% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -1078.291% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -22588.318% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -8804.602% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -36003.084% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -4699011.912% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -11997.445% |
| GB Sciences, Inc. | -1.36 Million USD | -51581.787% |
| Alpha Cognition Inc. | -13.77 Million USD | -5009.716% |
| HST Global, Inc. | -146.21 Thousand USD | -481220.703% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -40004.321% |
| Halberd Corporation | -79.67 Thousand USD | -883150.916% |
| Enzolytics Inc. | -2.17 Million USD | -32228.586% |
| Agentix Corp. | -1.37 Million USD | -51110.404% |
| Resverlogix Corp. | -3.61 Million USD | -19394.155% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -22089.916% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | -138.513% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 718201.02% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 10262.892% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -17613.069% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -23155.374% |
| AVAX Technologies, Inc. | -6.41 Million USD | -10872.523% |
| Zenith Capital Corp. | -10.59 Million USD | -6541.553% |
| Genscript Biotech Corporation | -95.47 Million USD | -637.077% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -3027776.258% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -16874.189% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1164247.944% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -34997.189% |
| Kadimastem Ltd | -3.3 Million USD | -21177.723% |
| Helix BioMedix, Inc. | -1.05 Million USD | -66538.354% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -159344.592% |
| LadRx Corporation | 400.44 Thousand USD | 175840.118% |
| Cell Source, Inc. | -5.32 Million USD | -13125.164% |
| Regen BioPharma, Inc. | 1.02 Million USD | 68857.548% |
| NovAccess Global Inc. | -4.76 Million USD | -14655.953% |
| Affymax, Inc. | -14.42 Million USD | -4778.945% |
| Itoco Inc. | -1.86 Million USD | -37553.338% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -15740.933% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -42065.309% |
| Mobile Lads Corp. | -2.26 Million USD | -30993.602% |
| CytoDyn Inc. | -49.84 Million USD | -1311.968% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -890336.906% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -308385.624% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -74644.272% |
| SYBLEU INC | -180.3 Thousand USD | -390206.926% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -43536.315% |
| International Stem Cell Corporation | -131 Thousand USD | -537105.344% |
| Bioxytran, Inc. | -4.28 Million USD | -16342.492% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -1296588.9% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -27713.055% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -1363.927% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -33189.451% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -90020.466% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -22113.984% |
| Neutra Corp. | -233.46 Thousand USD | -301332.335% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -3368.232% |
| PureTech Health plc | -65.69 Million USD | -971.189% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -3209.138% |
| IXICO plc | -1.17 Million USD | -59640.153% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -6989.141% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -1131.864% |
| CSL Limited | 2.64 Billion USD | 126.637% |
| Cellectis S.A. | -103.17 Million USD | -582.09% |